Medtronic applies for U.S. drug-eluting balloon approval; Dutch delivery biz completes brain cancer PhI;

> Medtronic ($MDT) submitted the first part of its FDA application to be the first on the U.S. market with a drug-eluting balloon. Its IN.PACT Admiral for peripheral artery disease is designed to treat atherosclerotic lesions in the superficial femoral artery with the delivery of Medtronic's FreePac technology, the coupling of an excipient with the drug paclitaxel. More from FierceMedicalDevices

> Dutch drug delivery company to-BBB completed a Phase I clinical trial of its G-Technology to deliver cancer drugs to the brain combining pegylated liposomes with a targeting ligand to get them across the blood-brain barrier. Release

> Atlantic Pharmaceuticals won a U.S. patent covering its Smart/Script abuse deterrent drug delivery system, designed to prevent overdosing of oral prescriptions and deter physical tampering of the drugs. Release

> InSite Vision snagged a U.S. patent for its drug delivery system with enhanced penetration of topical drugs into the eye. Report

And Finally... British engineers are using drug delivery technology as a model for products that could prevent damage to oil wells. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.